Active substance
Ivermectin
- SFDA 1
- US FDA 16
- Health Canada 4
- US price lines 7
- NHS prices 2
- WHO EML 3
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SOOLANTRA 10MG/GM CREAM | 10 mg/g | Cream · Topical | 1 Tube | SAR 82.85 | NCE · Prescription | GALDERMA | Valid |
Indications — CHI Daman Drug Formulary
HOOKWORM-CUTANEOUS LARVA MIGRANS; PAPULOPUSTULAR ROSACEA; SCABIES
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| STROMECTOL | 3MG | tablet · oral | MERCK SHARP DOHME | Prescription | 22 Nov 1996 |
| SKLICE | 0.5% | lotion · topical | ARBOR PHARMS LLC | Over-the-counter | 7 Feb 2012 |
| IVERMECTIN | 3MG | tablet · oral | EDENBRIDGE PHARMS | Prescription | 24 Oct 2014 |
| SOOLANTRA | 1% | cream · topical | GALDERMA LABS LP | Prescription | 19 Dec 2014 |
| IVERMECTIN | 1% | cream · topical | TEVA PHARMS USA | Prescription | 13 Sep 2019 |
| IVERMECTIN | 1% | cream · topical | PADAGIS ISRAEL | Prescription | 13 Apr 2020 |
| IVERMECTIN | 0.5% | lotion · topical | TARO | Over-the-counter | 6 May 2020 |
| IVERMECTIN | 1% | cream · topical | ZYDUS LIFESCIENCES | Prescription | 2 Aug 2022 |
| IVERMECTIN | 3MG | tablet · oral | SENORES PHARMS | Prescription | 16 Oct 2024 |
| IVERMECTIN | 3MG; 6MG | tablet · oral | RUBICON RESEARCH | Prescription | 22 Jan 2025 |
| IVERMECTIN | 3MG | tablet · oral | EPIC PHARMA LLC | Prescription | 9 Sep 2025 |
| IVERMECTIN | 3MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 26 Feb 2026 |
| IVERMECTIN | 3MG | tablet · oral | E5 PHARMA | Prescription | 9 Mar 2026 |
| IVERMECTIN | 3MG | tablet · oral | AJANTA PHARMA LTD | Prescription | 7 Apr 2026 |
| STROMECTOL | 6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | MERCK SHARP DOHME | Discontinued | 22 Nov 1996 |
| IVERMECTIN | 0.5% | lotion · topical | TEVA PHARMS USA | Discontinued | 21 Mar 2022 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PMS-IVERMECTIN | 02557363 | 1 % / W/W | CREAM · TOPICAL | PHARMASCIENCE INC |
| ROSIVER | 02440342 | 1 % / W/W | CREAM · TOPICAL | GALDERMA CANADA INC. |
| STROMECTOL | 02480557 | 3 MG | TABLET · ORAL | MERCK CANADA INC |
| ZDS-IVERMECTIN CREAM | 02568098 | 1 % / W/W | CREAM · TOPICAL | ZYDUS LIFESCIENCES LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | IVERMECTIN 0.5% LOTION | $1.23937 | per GM | 23 Sep 2026 |
| US NADAC | IVERMECTIN 1% CREAM | $2.74609 | per GM | 23 Sep 2026 |
| US NADAC | IVERMECTIN 3 MG TABLET | $1.99423 | per EA | 23 Sep 2026 |
| US NADAC | IVERMECTIN 6 MG TABLET | $9.80491 | per EA | 23 Sep 2026 |
| US NADAC | SKLICE 0.5% LOTION | $0.28538 | per GM | 23 Sep 2026 |
| US NADAC | SOOLANTRA 1% CREAM | $15.5092 | per GM | 23 Sep 2026 |
| US NADAC | STROMECTOL 3 MG TABLET | $4.4593 | per EA | 19 Nov 2025 |
| NHS Drug Tariff | Ivermectin 10mg/g cream | £36.58 | 60 gram | 1 Oct 2026 |
| NHS Drug Tariff | Ivermectin 3mg tablets | £83.58 | 4 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.1.1. Intestinal anthelminthics · core
Hookworm diseases; Strongyloidiasis; Trichuriasis; Ancylostomiasis; Ascariasis
Oral > Solid > tablet: 3 mg - 6.1.2. Antifilarials · core
Lymphatic filariasis; Onchocerciasis
Oral > Solid > tablet: 3 mg - 6.6. Medicines for ectoparasitic infections · core
Scabies
Oral > Solid > tablet: 3 mg
Safety signals and safety-related labeling changes
- US FDA 14 Oct 2022 SOOLANTRA — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 Mar 2022 STROMECTOL — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 16 Jun 2017 SKLICE — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.